CARE Fertility Donates effortless IVF Treatment to Support Family Building Grant

Friday, September 20, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Grant to be introduced at National Polycystic Ovary Syndrome Association Gala

DALLAS, Sept. 19, 2019 /PRNewswire-PRWeb/ -- The Center for Assisted Reproduction, CARE Fertility, announces sponsorship

of the National Polycystic Ovary Syndrome Association Gala being held Friday, September 20, 2019 at the Alfond Inn, Winter Park, Florida. The National Polycystic Ovary Syndrome Association, called PCOS Challenge, is a nonprofit patient support and advocacy organization that is advancing the cause for women and girls with PCOS. Serving more than 50,000 members globally, the organization will be introducing a new "Family Building Grant," which will include an effortless IVF® treatment from CARE Fertility.

"PCOS is a complex hormonal and reproductive disorder that affects up to 15% of women in the U.S., and is a leading cause of infertility in women," said Kevin Doody, M.D., CARE Fertility co-founder. "The effortless IVF treatment is an effective option for women with PCOS because the innovation requires lower medication dosages with less doctor visits. We look forward to supporting the Family Building Grant and offering new hope to those struggling with infertility."

The Family Building Grant will be announced during the PCOS Rise to the Challenge Gala, which is expected to raise awareness and funds for the 501(c)(3) nonprofit's research, health screenings, television and radio programming, support groups and education initiatives.

"We are grateful to sponsors like CARE Fertility for providing innovative treatments and services that will make a difference in the lives of women with PCOS," said Sasha Ottey, executive director of PCOS Challenge. "The introduction of the Family Building Grant will be welcomed with much anticipation."

The effortless IVF (in vitro fertilization) procedure is a new, disruptive technology that greatly reduces costs, time and has success rates comparable to traditional IVF. This treatment is "effortless" because the procedure requires only two or three doctor visits prior to egg retrieval compared to eight appointments with traditional IVF.

"We are proud to support PCOS Challenge because we have a complementary mission to make fertility treatment more accessible," adds Kathy Doody, M.D., co-founder of CARE Fertility. "For couples who don't live near a fertility center, the effortless IVF process allows them to make appointments in advance with less disruption to their busy lives and work schedules. Through the Family Building Grant, we are excited to make the dreams of starting a family become a reality."

About PCOS Challenge Serving over 50,000 members, PCOS Challenge: The National Polycystic Ovary Syndrome Association is the leading 501(c)(3) nonprofit organization globally that is advancing the cause for women with PCOS. The organization touches the lives of women with PCOS and their supporters each year through research, grants, health screenings, television and radio programming, support groups, and education and awareness initiatives. Learn more at

About Center for Assisted Reproduction The Center for Assisted Reproduction (CARE Fertility) is a pioneer in assisted reproductive technologies in the north Texas region with several firsts including the first ICSI pregnancies and the first to successfully implement a blastocyst culture system. With two state-of-the-art facilities in Bedford and Fort Worth, Texas, CARE Fertility offers the full gamut of fertility and assisted reproductive technology treatments. CARE Fertility is the most experienced practice offering effortless IVF®, and the first in the world to use the INVOcell device blastocyst embryo transfer. CARE Fertility can offer effortless IVF at half the cost of traditional IVF due to lower dose of medications and minimal monitoring — all while maintaining high success rates. Learn more at, on Facebook, Twitter and Instagram @CAREFertilityUS.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z



Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store